The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Stock and Other Ownership Interests - MedSIR; Thummi
Consulting or Advisory Role - AstraZeneca; Bayer; Boehringer Ingelheim; Daiichi Sankyo Pharmaceutical; Eisai; GlaxoSmithKline; Lilly O.; MSD; Novartis; Pfizer; Roche/Genentech; Sanofi; Zodiac Pharma
Research Funding - AB Science (Inst); Abbvie (Inst); Abraxis BioScience (Inst); Amgen (Inst); Asana Biosciences (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Biomarin (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo Pharmaceutical (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Henlius (Inst); ImClone Systems (Inst); Leo Pharma (Inst); Lilly O. (Inst); Medivation (Inst); Merck (Inst); Merck KGaA (Inst); Merrimack (Inst); Millennium (Inst); Mylan (Inst); Novartis (Inst); Pfizer (Inst); Polyphor (Inst); Roche/Genentech (Inst); Sanofi (Inst); Shanghai Allist Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst)
 
Honoraria - AstraZeneca; Eisai; Pfizer; Roche
Consulting or Advisory Role - Novartis
Phase III NATALEE trial of ribociclib + endocrine therapy as adjuvant treatment in patients with HR+/HER2− early breast cancer.
 
Dennis J. Slamon
Leadership - 1200 Pharma; Biomarin; Torl Biotherapeutics
Stock and Other Ownership Interests - Amgen; Amgen; BioMarin; Merck Sharp & Dohme; Pfizer; Seagen; Vertex
Honoraria - Novartis
Consulting or Advisory Role - Lilly; Novartis; Pfizer; Seagen
Research Funding - Novartis; Pfizer
Travel, Accommodations, Expenses - Biomarin; Novartis; Pfizer
 
Daniil Stroyakovskiy
No Relationships to Disclose
 
Denise A. Yardley
Consulting or Advisory Role - AstraZeneca (Inst); Athenex (Inst); Biotheranostics (Inst); G1 Therapeutics (Inst); Gilead Sciences (Inst); Immunomedics (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Sanofi/Aventis (Inst)
Research Funding - Abbvie (Inst); Ambrx (Inst); Amgen (Inst); Biomarin (Inst); Biothera (Inst); Clovis Oncology (Inst); Dana Farber Cancer Hospital (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Incyte (Inst); Innocrin Pharma (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Medivation (Inst); Merck (Inst); Merrimack (Inst); Nektar (Inst); Novartis (Inst); NSABP Foundation (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Polyphor (Inst)
 
Chiun-Sheng Huang
Honoraria - AstraZeneca; Daiichi Sankyo; Lilly; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Daiich Sankyo; Lilly; Novartis; Pfizer; Roche
Speakers' Bureau - Daiich Sankyo; Roche
Research Funding - AstraZeneca (Inst); Daiichi Sankyo (Inst); EirGenix (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); OBI Pharma (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Pfizer; Roche
 
Peter A. Fasching
Honoraria - Agendia; AstraZeneca; BionTech (Inst); Cepheid (Inst); Daiichi Sankyo; Eisai; Gilead Sciences; Hexal; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Pierre Fabre; Roche; Seagen
Consulting or Advisory Role - Agendia; AstraZeneca; Daiichi Sankyo; Eisai; Gilead Sciences; Hexal; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Pierre Fabre; Roche; Seagen
Research Funding - BioNTech (Inst); Cepheid (Inst); Novartis (Inst); Roche
 
John Crown
Employment - OncoAssure; OncoMark
Stock and Other Ownership Interests - OncoAssure; OncoMark
Honoraria - AstraZeneca; MSD Oncology; Pfizer; Pierre Fabre
Consulting or Advisory Role - AstraZeneca; MSD Oncology
Speakers' Bureau - Pfizer
Research Funding - BMS GmbH & Co. KG (Inst); MSD Oncology (Inst); Novartis (Inst); Puma Biotechnology (Inst); Regeneron (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - WO2020011770 (A1) - A method of predicting response to treatment in cancer patients
Travel, Accommodations, Expenses - Astrazeneca; Daiichi Sankyo Europe GmbH; MSD; Pfizer; Regeneron; Roche
 
Aditya Bardia
Consulting or Advisory Role - bioTheranostics; Daiichi Sankyo/Astra Zeneca; Foundation Medicine; Genentech; Genentech/Roche (Inst); Immunomedics; Immunomedics (Inst); Innocrin Pharma (Inst); Merck; Novartis; Novartis (Inst); Pfizer; Pfizer (Inst); Philips Healthcare; Puma Biotechnology; Radius Health; Radius Health (Inst); Sanofi; Spectrum Pharmaceuticals
Research Funding - AstraZeneca/Daiichi Sankyo (Inst); Genentech (Inst); Immunomedics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Radius Health (Inst); Sanofi (Inst)
 
Stephen Chia
Consulting or Advisory Role - Lilly O.; Novartis; Pfizer; Roche
Research Funding - Lilly O. (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
 
Seock-Ah Im
Consulting or Advisory Role - Amgen; AstraZeneca; Daiichi Sankyo; Eisai; GlaxoSmithKline; Hanmi; Lilly; MSD; Novartis; Pfizer; Roche/Genentech
Research Funding - AstraZeneca (Inst); Boryung Pharmaceuticals (Inst); Daewoong Pharmaceutical (Inst); Eisai (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Other Relationship - Roche
 
Miguel Martin
Honoraria - Lilly; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; SEAGEN
Consulting or Advisory Role - AstraZeneca; Daiichi-Sankyo; Lilly; Novartis; Pfizer; Roche/Genentech
Speakers' Bureau - Lilly/ImClone; Lilly/ImClone; Pierre Fabre; Roche/Genentech
Research Funding - Novartis (Inst); Puma Biotechnology (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Daichii-Sankyo
Other Relationship - Novartis; Roche
 
Sherene Loi
Consulting or Advisory Role - Aduro Biotech (Inst); AstraZeneca (Inst); BMS (Inst); Daiichi Sankyo/Lilly (Inst); G1 Therapeutics (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Pfizer (Inst); PUMA Biotechnology (Inst); Roche/Genentech (Inst); Seagen (Inst); Silverback Therapeutics (Inst); Tallac Therapeutics (Inst)
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst); Seagen (Inst)
Other Relationship - Roche Medical writing support
 
Binghe Xu
No Relationships to Disclose
 
Sara A. Hurvitz
Stock and Other Ownership Interests - Ideal Implant (I); ROM Tech (I)
Honoraria - Daiichi Sankyo/Astra Zeneca
Research Funding - Ambryx (Inst); Amgen (Inst); Arvinas (Inst); AstraZeneca/Daiichi Sankyo (Inst); Bayer (Inst); Biomarin (Inst); Cascadian Therapeutics (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dantari (Inst); Dignitana (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Greenwich LifeSciences (Inst); Immunomedics (Inst); Lilly (Inst); Macrogenics (Inst); Merrimack (Inst); Novartis (Inst); OBI Pharma (Inst); Orinove (Inst); Pfizer (Inst); Phoenix Molecular Designs (Inst); Pieris Pharmaceuticals (Inst); Puma Biotechnology (Inst); Radius Health (Inst); Samumed (Inst); sanofi (Inst); Seagen (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Lilly
Other Relationship - Pfizer; Roche
 
Carlos Barrios
No Relationships to Disclose
 
Michael Untch
Honoraria - Agendia (Inst); Amgen (Inst); Art tempi (Inst); AstraZeneca (Inst); Baxter (Inst); Daiji Sankyo (Inst); Eisai Europe (Inst); Gilead Sciences (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche Pharma AG (Inst); Sanofi (Inst); Seagen (Inst)
Consulting or Advisory Role - Agendia (Inst); Amgen (Inst); Art tempi (Inst); AstraZeneca (Inst); Daiichi Sankyo Europe GmbH (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Medac (Inst); MSD Oncology (Inst); Myriad Genetics (Inst); Novartis (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche Pharma AG (Inst); Sanofi Aventis GmbH (Inst)
 
Rebecca L. Moroose
Consulting or Advisory Role - Johnson & Johnson
Speakers' Bureau - Genentech; Gilead Sciences; Lilly O.; Pfizer; Seagen
 
Fran Visco
No Relationships to Disclose
 
Rodrigo Fresco
Other Relationship - Novartis (Inst)
 
Tetiana Taran
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Gabriel N. Hortobagyi
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Novartis; Seagan
Research Funding - Novartis (Inst)